HIKMA PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,913 GBX | +3.18% |
|
+6.34% | +6.93% |
| Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets |  |
| Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
ETFs positioned on Hikma Pharmaceuticals PLC
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.44% | 1,120 M€ | +0.40% | ||
| 0.25% | 3 M€ | +9.95% | - | |
| 0.20% | 11 M€ | +0.83% | - | |
| 0.16% | 18 M€ | +3.79% | - | |
| 0.15% | 5 M€ | +10.09% | - | |
| 0.15% | 14 M€ | +5.66% | - | |
| 0.04% | 6 M€ | -.--% | ||
| 0.02% | 10 M€ | -3.35% | - | |
| 0.01% | 31 M€ | +3.50% | - | |
| 0.01% | 284 M€ | -.--% | ||
| 0.01% | 206 M€ | -.--% | ||
| 0.01% | 1,166 M€ | +0.26% | - | |
| 0.01% | 607 M€ | +0.05% | - | |
| 0.01% | 23 M€ | -.--% | - | |
| 0.01% | 786 M€ | -.--% | ||
| 0.01% | 273 M€ | +15.83% | ||
| 0.00% | 389 M€ | +6.83% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 34 M€ | +4.85% | - | |
| 0.00% | 237 M€ | +2.89% | - | |
| 0.00% | 302 M€ | +3.80% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 26 M€ | -4.70% | - |
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:
- generic injectable products (45.3%);
- brand name drugs (27.5%);
- generic products taken orally (26.7%);
- other (0.5%).
Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
23.83
USD
Average target price
28.64
USD
Spread / Average Target
+20.20%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.93% | 5.29B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HIK Stock
- Funds and ETFs Hikma Pharmaceuticals PLC
